1
|
Alrashed RF, Alkhuwaylidi AA, Aldashash KA, Albati NA, Algarni AA, Almodhaiberi H, Al Hasan I. Peritoneal Tuberculosis in a Young Healthy Male Resembling Intra-Abdominal Malignancy. Cureus 2021; 13:e20677. [PMID: 35106218 PMCID: PMC8784981 DOI: 10.7759/cureus.20677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/25/2021] [Indexed: 11/05/2022] Open
Abstract
Intra-peritoneal tuberculosis is a rare disease, accounting for 1-2% of all tuberculosis cases. The absence of characteristic clinical picture of intra-peritoneal tuberculosis makes the diagnosis rarely easy for clinicians as it mimics malignancy. We present a case of a young male patient who presented with peritoneal tuberculosis, aiming to contribute to a better understanding of peritoneal tuberculosis in the literature.
Collapse
Affiliation(s)
- Rema F Alrashed
- Department of Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | | | - Khloud A Aldashash
- Department of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, SAU
| | - Naif A Albati
- Department of Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| | | | | | - Ibrahim Al Hasan
- Department of Surgery, Prince Sultan Military Medical City, Riyadh, SAU
| |
Collapse
|
2
|
Sek KSY, Tsang I, Lee XY, Albaqmi OH, Morosan Allo YJ, Rosmarin MC, Mahrous AK, Parameswaran R, Ng DCE, Tong AKT, Loke KSH, Brenta G, Alghamdi AH, Albati NA, Fish SA, Tuttle RM, Yang SP. Frequent neck US in papillary thyroid cancer likely detects non-actionable findings. Clin Endocrinol (Oxf) 2021; 94:504-512. [PMID: 32886805 DOI: 10.1111/cen.14325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 08/17/2020] [Accepted: 08/18/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND American Thyroid Association (ATA) low-intermediate-risk papillary thyroid cancer (PTC) patients without structural and biochemical evidence of disease on initial post-treatment evaluation have a low risk of recurrence. Studies have shown that with current ultrasound scans (US) and thyroglobulin assays, recurrences mostly occurred 2-8 years after initial therapy. The ATA recommends that neck US be done 6-12 months after surgery to establish patient's response to therapy, then periodically depending on risk of recurrence. The lack of clarity in recommendations on timing of follow-up US and fear of recurrence leads to frequent tests. OBJECTIVES To evaluate the utility of routine neck US in ATA low-intermediate-risk PTC patients with no structural disease on neck US and non-stimulated thyroglobulin <1.0 ng/mL after initial therapy. METHODS A retrospective study of 93 patients from Singapore, Saudi Arabia and Argentina with ATA low (n = 49) to intermediate (n = 44) risk PTC was conducted between 1998 and 2017. The outcome was to measure the frequency of identifying structural disease recurrence and non-actionable US abnormalities. RESULTS Over a median follow-up of 5 years, five of the 93 patients (5.4%) developed structural neck recurrence on US at a median of 2.5 years after initial treatment. Indeterminate US abnormalities were detected in 19 of the 93 patients (20.4%) leading to additional tests, which did not detect significant disease. CONCLUSION In ATA low-intermediate-risk PTC with no suspicious findings on neck US and a non-stimulated thyroglobulin of <1.0 ng/mL after initial therapy, frequent US is more likely to identify non-actionable abnormalities than clinically significant disease.
Collapse
Affiliation(s)
- Kathleen Su-Yen Sek
- Department of Endocrinology, National University Health System Singapore, Singapore City, Singapore
| | - Ingrid Tsang
- Department of Endocrinology, Tseung Kwan O Hospital, Hong Kong, Hong Kong
| | - Xuan Yong Lee
- Department of Medicine, National University Health System Singapore, Singapore City, Singapore
| | - Omar H Albaqmi
- Department of Surgery, Breast Endocrine Surgery Unit, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Yanina Jimena Morosan Allo
- Department of Endocrinology and Metabolism, Unidad Asistencial Dr. Cesar Milstein Buenos Aires, Buenos Aires, Argentina
| | - Melanie Cinthia Rosmarin
- Department of Endocrinology and Metabolism, Unidad Asistencial Dr. Cesar Milstein Buenos Aires, Buenos Aires, Argentina
| | - Azhar K Mahrous
- Department of Internal Medicine, Imam Muhammad Ibn Saud Islamic University, College of Medicine, Riyadh, Saudi Arabia
| | - Rajeev Parameswaran
- Department of Endocrine Surgery, National University Hospital, Singapore City, Singapore
| | - David Chee Eng Ng
- Department of Nuclear Medicine, Singapore General Hospital, Singapore City, Singapore
| | - Aaron Kian Ti Tong
- Department of Nuclear Medicine, Singapore General Hospital, Singapore City, Singapore
| | - Kelvin Siu Hoong Loke
- Department of Nuclear Medicine, Singapore General Hospital, Singapore City, Singapore
| | - Gabriela Brenta
- Department of Endocrinology and Metabolism, Unidad Asistencial Dr. Cesar Milstein Buenos Aires, Buenos Aires, Argentina
| | - Abdullah Hassan Alghamdi
- Department of Surgery, Breast Endocrine Surgery Unit, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Naif A Albati
- Department of Surgery, Breast Endocrine Surgery Unit, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Stephanie A Fish
- Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - R Michael Tuttle
- Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
| | - Samantha Peiling Yang
- Department of Endocrinology, National University Hospital, Singapore City, Singapore
- Yong Loo Lin School of Medicine, Singapore City, Singapore
| |
Collapse
|
3
|
Albati NA, Korairi AA, Al Hasan I, Almodhaiberi HK, Algarni AA. Outcomes of staged hepatectomies for liver malignancy. World J Hepatol 2019; 11:513-521. [PMID: 31293719 PMCID: PMC6603508 DOI: 10.4254/wjh.v11.i6.513] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Revised: 05/27/2019] [Accepted: 06/18/2019] [Indexed: 02/06/2023] Open
Abstract
Liver malignancies are the fifth most common cause of death worldwide. Surgical intervention with curative intent is the treatment of choice for liver tumors as it provides long-term survival. However, only 20% of patients with metastatic liver lesions can be managed by curative liver resection. In most of the cases, hepatectomy is not feasible because of insufficient future liver remnant (FLR). Two-stage hepatectomy is advocated to achieve liver resection in a patient who is considered to not be a candidate for resection. Procedures of staged hepatectomy include conventional two-stage hepatectomy, portal vein embolization, and associating liver partition and portal vein ligation for a staged hepatectomy. Technical success is high for each of these procedures but variable between them. All the procedures have been reported as being effective in achieving a satisfactory FLR and completing the second-stage resection. Moreover, the overall survival and disease-free survival rates have improved significantly for patients who were otherwise considered nonresectable; yet, an increase in the morbidity and mortality rates has been observed. We suggest that this type of procedure should be carried out in high-flow centers and through a multidisciplinary approach. An experienced surgeon is key to the success of those interventions.
Collapse
Affiliation(s)
- Naif A Albati
- Hepatobiliary and Liver Transplant Unit, Department of General Surgery, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia
| | - Ali A Korairi
- Hepatobiliary and Liver Transplant Unit, Department of General Surgery, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia
| | - Ibrahim Al Hasan
- Hepatobiliary and Liver Transplant Unit, Department of General Surgery, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia
| | - Helayel K Almodhaiberi
- Hepatobiliary and Liver Transplant Unit, Department of General Surgery, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia
| | - Abdullah A Algarni
- Hepatobiliary and Liver Transplant Unit, Department of General Surgery, Prince Sultan Military Medical City, Riyadh 11159, Saudi Arabia
| |
Collapse
|